Patent invalidation or circumvention
Branded pharmaceutical sales depend on enforceable intellectual property protection.
- Scope
- Key products with patent protection
- Materiality
- high
Organon & Co.
Organon & Co. is a U.S.-based global healthcare company focused on women’s health and general medicines, including biosimilars. Its portfolio spans more than 70 products sold in over 140 countries and territories through wholesalers, retailers, hospitals, government agencies, and managed healthcare organizations.
53,3 %
3,0 %
−2,9 %
1.82
1.23
| % | |
|---|---|
| Women’s Health | 45% Prescription products used in contraception and other women’s health needs. |
| General Medicines | 35% Established branded medicines used across primary and specialty care. |
| Biosimilars | 20% Biologic follow-on medicines commercialized through external partners. |
Organon sells primarily to healthcare intermediaries rather than directly to end consumers, including wholesalers,...
- Drug wholesalersprimary
Buy in bulk for downstream distribution and are central to U.S. and international channel access.
- Managed healthcare providersprimary
Health plans, PBMs, and HMOs that shape formulary access, rebates, and patient uptake.
- Hospitals and clinicssecondary
Purchase medicines used in institutional care settings and specialty treatment pathways.
- Government agenciessecondary
Public-sector buyers that procure medicines for national or regional health programs.
- Retail pharmaciessecondary
Dispense branded prescription products to patients through prescription fulfillment.
Organon operates globally, with products sold in more than 140 countries and territories...
- •Products are sold in over 140 countries and territories
- •Manufacturing sites are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the UK
- •The United States is a key commercial and reimbursement market
- •International operations expose the company to FX, tariffs, and local regulation
- •Global channel mix includes wholesalers, hospitals, and public-sector buyers
Organon’s strategy centers on women’s health, maintaining a broad portfolio of established medicines, and expanding...
01
Deepen women’s health franchisemedium-term
Women’s health is the company’s defining therapeutic focus and a major source of brand recognition.
02
Leverage external partnerships for biosimilarsmedium-term
Partnering reduces the need to build all development and manufacturing capabilities internally.
03
Improve market access and channel executionshort-term
Prescription medicines depend on reimbursement, wholesaler stocking, and formulary access.
Organon faces patent, regulatory, manufacturing, and supply-chain risks typical of branded pharmaceuticals, with added...
Biosimilar regulatory and execution risk
Biosimilars require complex development, approval, and partner execution.
- Scope
- Biosimilar portfolio
- Materiality
- high
Manufacturing and supply disruption
The company relies on a limited set of manufacturing sites and third-party inputs.
- Scope
- Global supply chain and six manufacturing facilities
- Materiality
- high
Regulatory and compliance enforcement
Pharmaceutical promotion, pricing, and product approvals are heavily regulated.
- Scope
- U.S. FDA and international markets
- Materiality
- high
Channel inventory and rebate volatility
Wholesaler stocking, chargebacks, and rebates can materially affect reported revenue.
- Scope
- U.S. and managed-care channels
- Materiality
- high
Gross-to-net revenue deductions
Affects net revenue and quarterly comparability
Customer discount accruals
Can create accrual adjustments if assumptions change
Accounts receivable factoring
Affects operating cash flow and working capital
Contingent consideration
Impacts other expense and acquisition accounting
Intangible asset impairment
Could lead to non-cash impairment charges
: 29.4.2026